Jackson Wealth Management LLC Acquires 633 Shares of Gilead Sciences, Inc. $GILD

Jackson Wealth Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,747 shares of the biopharmaceutical company’s stock after buying an additional 633 shares during the period. Jackson Wealth Management LLC’s holdings in Gilead Sciences were worth $526,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the first quarter worth approximately $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the first quarter worth approximately $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.9%

Shares of GILD stock opened at $112.69 on Friday. The stock’s fifty day moving average price is $114.34 and its two-hundred day moving average price is $109.92. The company has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a fifty-two week low of $83.98 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GILD. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Saturday, September 27th. Finally, Rothschild & Co Redburn increased their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.